📰 Treating Fields News
Page 6 - Treating Fields News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Treating Fields. Real-time updates on events, politics, business and more.
March 24, 2022
Patients in phase 2 pilot trial 2-THE-TOP had median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14 Novocure (NASDAQ: NVCR) today announced
March 23, 2022
Pre-specified interim analysis concluded that the INNOVATE-3 study should proceed to final analysis as planned Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis
February 28, 2022
ST. HELIER, Jersey--(BUSINESS WIRE)--Feb 28, 2022--
February 25, 2022
St. Helier, Jersey – Novocure (NASDAQ: NVCR) announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Tr
February 24, 2022
Todd Longsworth's work was foundational to the growth of Novocure in becoming a global oncology company Barak Ben Arye has been appointed to General Counsel, effective April 1 Novocure (NASDAQ:
February 24, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
October 28, 2021
Final data from INNOVATE-3 trial anticipated in 2023 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of
October 28, 2021
NVCR earnings call for the period ending September 30, 2021.
October 4, 2021
Final data collection is expected in the first half of 2022 Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab
June 3, 2021
/PRNewswire/ -- The EndBrainCancer Initiative (EBCI) recently hosted the first of a virtual "Know Your Treatment Options" Patient Education Meeting and Event...